Try a new search

Format these results:

Searched for:

in-biosketch:true

person:frontj01

Total Results:

254


Mechanical Thrombectomy in Nonagenarians: A Propensity Score Matched Analysis

Agarwal, Shashank; Huang, Jeffrey; Scher, Erica; Farkas, Jeffrey; Arcot, Karthikeyan; Gordon, David; Turkel-Parrella, David; Tiwari, Ambooj; Liff, Jeremy; Yaghi, Shadi; Dehkharghani, Seena; Ishida, Koto; Riina, Howard; Frontera, Jennifer A
BACKGROUND:Little data exists on outcomes of mechanical thrombectomy (MT) in nonagenarians. We aimed to compare the procedural and discharge outcomes of MT for acute ischemic stroke (AIS) in nonagenarians versus younger patients. METHODS:Procedural outcomes and discharge disposition were compared in propensity score-matched groups of nonagenarians versus patients aged≤69 with AIS who underwent MT. Patients aged 70-89 were excluded in order to compare nonagenarians to a younger cohort that most closely approximates the age of patients in the seminal MT trials. Good discharge disposition was defined as a discharge to home or acute rehabilitation. RESULTS:Of 3010 AIS patients, 46/297(16%) nonagenarians underwent MT compared to 159/1337(12%) aged≤69 (P = 0.091). Of 78 propensity score-matched patients (N = 39 ≥90, N = 39 ≤69), the median admission NIHSS was 22 versus 20, median ASPECTS was 9 versus 9, pre-stroke mRS<4 was 82% versus 87%, 18% versus 8% received IV tPA, and mTICI≥2b was 90% versus 90%, respectively (all P>0.05). Revascularization time (569 versus 372 min), door to groin puncture time (82 versus 71 min) and groin puncture to revascularization times (39 versus 24 min) were similar in between nonagenarians and ≤69, respectively (both P>0.05). Symptomatic ICH (2.6% versus 10.3%; p = 0.165) and in-hospital death rates (10% vs 26%; p = 0.077) trended lower among nonagenarians versus aged≤69. Good discharge disposition occurred in 44% of nonagenarians versus 51% aged≤69 years (p = 0.496). CONCLUSIONS:In propensity score analysis, 90% of nonagenarians achieved successful recanalization and almost half (44%) were discharged to home/acute rehabilitation, which was similar to a younger (aged≤69 years) cohort.
PMID: 32414578
ISSN: 1532-8511
CID: 4438332

Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke

Valderrama, Eduard Valdes; Humbert, Kelley; Lord, Aaron; Frontera, Jennifer; Yaghi, Shadi
PMID: 32396456
ISSN: 1524-4628
CID: 4431112

This is your brain on LVAD [Editorial]

Frontera, Jennifer A
PMID: 32061353
ISSN: 1557-3117
CID: 4313032

Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo

Agarwal, Shashank; Scher, Erica; Lord, Aaron; Frontera, Jennifer; Ishida, Koto; Torres, Jose; Rostanski, Sara; Mistry, Eva; Mac Grory, Brian; Cutting, Shawna; Burton, Tina; Silver, Brian; Liberman, Ava L; Lerario, Mackenzie P; Furie, Karen; Grotta, James; Khatri, Pooja; Saver, Jeffrey; Yaghi, Shadi
Background and Purpose- The first of the 2 NINDS (National Institute of Neurological Disorders and Stroke) Study trials did not show a significant increase in early neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) improvement by ≥4, with alteplase treatment. We hypothesized that early neurological improvement defined as a percentage change in NIHSS (percent change NIHSS) at 24 hours is superior to other definitions in predicting 3-month functional outcomes and using this definition there would be treatment benefit of alteplase over placebo at 24 hours. Methods- We analyzed the NINDS rt-PA Stroke Study (Parts 1 and 2) trial data. Percent change NIHSS was defined as ([admission NIHSS score-24-hour NIHSS score]×100/admission NIHSS score] and delta NIHSS as (admission NIHSS score-24-hour NIHSS score). We compared early neurological improvement using these definitions between alteplase versus placebo patients. We also used receiver operating characteristic curve to determine the predictive association of early neurological improvement with excellent 3-month functional outcomes (Barthel Index score of 95-100 and modified Rankin Scale score of 0-1), good 3-month functional outcome (modified Rankin Scale score of 0-2), and 3-month infarct volume. Results- There was a significantly greater improvement in the 24-hour median percent change NIHSS among patients treated with alteplase compared with the placebo group (28% versus 15%; P=0.045) but not median delta NIHSS (3 versus 2; P=0.471). Receiver operating characteristic curve comparison showed that percent change NIHSS (ROCpercent) was better than delta NIHSS (ROCdelta) and admission NIHSS (ROCadmission) with regards to excellent 3-month Barthel Index (ROCpercent, 0.83; ROCdelta, 0.76; ROCadmission, 0.75), excellent 3-month modified Rankin Scale (ROCpercent, 0.83; ROCdelta, 0.74; ROCadmission, 0.78), and good 3-month modified Rankin Scale (ROCpercent, 0.83; ROCdelta, 0.76; ROCadmission, 0.78). Conclusions- In the NINDS rt-PA trial, alteplase was associated with a significant percent change improvement in NIHSS at 24 hours. Percent change in NIHSS may be a better surrogate marker of thrombolytic activity and 3-month outcomes.
PMID: 32102629
ISSN: 1524-4628
CID: 4323492

Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage

Frontera, Jennifer A; Bhatt, Prachi; Lalchan, Rebecca; Yaghi, Shadi; Ahuja, Tania; Papadopoulos, John; Joset, Danielle
Andexanet-alpha is a specific reversal agent for direct factor Xa inhibitors (dFXaI). We aimed to project utilization rates and cost of andexanet for reversal of dFXaI-related major hemorrhage compared to 4-factor prothrombin complex concentrates (4F-PCC). A retrospective, multicenter review was conducted between 1/1/2014 and 7/15/2018 of patients who received 4F-PCC for reversal of dFXaI-related life-threatening hemorrhages. Total hospital reimbursements/patient were calculated based on national average MS-DRG payments adjusting for Medicare discounts. The projected cost for andexanet (based on dose and insurance) and % reimbursement/patient was compared to the actual cost of 4F-PCC. Hemostasis at 24 h (excellent/good vs. poor) and 30-day thrombotic complications were assessed. Of 126 patients who received 4F-PCC to reverse dFXaI, 46 (~ 10 per-year) met inclusion criteria. The median projected cost of andexanet was $22,120/patient, compared to $5670/patient for 4F-PCC (P < 0.001). The median hospital reimbursement was $11,492/hospitalization. The projected cost of andexanet alone would exceed the entire hospital reimbursement in 74% of patients by a median of $7604, while 4F-PCC cost exceeded the total hospital payments in 7% of patients in the same cohort (P < 0.001). Hemostasis was excellent/good in 72% of patients post-4F-PCC, compared to 82% in andexanet trials. Thromboembolic events occurred in 4% of patients following 4F-PCC versus 10% in andexanet trials. The projected cost of andexanet would exceed the national average hospital reimbursement/patient in nearly 75% of patients by over $7500/hospitalization. 4F-PCC was significantly less expensive, had lower rates of thrombosis, but also lower rates of good/excellent hemostasis compared to published data for andexanet.
PMID: 31664662
ISSN: 1573-742x
CID: 4162322

SARS-CoV-2 Is Not Detected in the Cerebrospinal Fluid of Encephalopathic COVID-19 Patients

Placantonakis, Dimitris G; Aguero-Rosenfeld, Maria; Flaifel, Abdallah; Colavito, John; Inglima, Kenneth; Zagzag, David; Snuderl, Matija; Louie, Eddie; Frontera, Jennifer Ann; Lewis, Ariane
Neurologic manifestations of the novel coronavirus SARS-CoV-2 infection have received wide attention, but the mechanisms remain uncertain. Here, we describe computational data from public domain RNA-seq datasets and cerebrospinal fluid data from adult patients with severe COVID-19 pneumonia that suggest that SARS-CoV-2 infection of the central nervous system is unlikely. We found that the mRNAs encoding the ACE2 receptor and the TMPRSS2 transmembrane serine protease, both of which are required for viral entry into host cells, are minimally expressed in the major cell types of the brain. In addition, CSF samples from 13 adult encephalopathic COVID-19 patients diagnosed with the viral infection via nasopharyngeal swab RT-PCR did not show evidence for the virus. This particular finding is robust for two reasons. First, the RT-PCR diagnostic was validated for CSF studies using stringent criteria; and second, 61% of these patients had CSF testing within 1 week of a positive nasopharyngeal diagnostic test. We propose that neurologic sequelae of COVID-19 are not due to SARS-CoV-2 meningoencephalitis and that other etiologies are more likely mechanisms.
PMCID:7759491
PMID: 33362695
ISSN: 1664-2295
CID: 4731452

Predicting Symptomatic Intracranial Hemorrhage After Mechanical Thrombectomy: The TAG Score [Meeting Abstract]

Montalvo, Mayra; Mistry, Eva; Chang, Andrew; Yakhkind, Aleksandra; Dakay, Katarina; Azher, Idrees; Mistry, Akshitkumar; Chitale, Rohan; Cutting, Shawna; Burton, Tina; Mac Grory, Brian; Reznik, Michael; Mahta, Ali; Thompson, Bradford; Ishida, Koto; Frontera, Jennifer; Riina, Howard; Gordon, David; Turkel-Parrella, David; Scher, Erica; Farkas, Jeffrey; McTaggart, Ryan A.; Khatri, Pooja; Furie, Karen; Jayaraman, Mahesh; Yaghi, Shadi
ISI:000536058001210
ISSN: 0028-3878
CID: 4561172

TIME IS BRAIN in mechanical thrombectomy Particularly in Those Arriving within 6 hours and have good ASPECTS score [Meeting Abstract]

Snyder, Thomas; Agarwal, Shashank; Flusty, Brent; Kim, Sun; Frontera, Jennifer; Lord, Aaron; Favate, Albert; Humbert, Kelley; Torres, Jose; Sanger, Matthew; Zhang, Cen; Ishida, Koto; Rostanski, Sara; Yaghi, Shadi
ISI:000536058003240
ISSN: 0028-3878
CID: 4561342

Poor Risk Factor Control And Lower Levels Of Physical Activity Predict Incident Major Cardiovascular Events In Patients With Symptomatic Vertebrobasilar Disease: A Post-hoc Analysis Of The SAMMPRIS Trial [Meeting Abstract]

Croll, Leah; Chang, Andrew; Scher, Erica; Ishida, Koto; Torres, Jose; Riina, Howard; Frontera, Jennifer; Lord, Aaron; Yaghi, Shadi
ISI:000536058001201
ISSN: 0028-3878
CID: 4561162

The National Institutes of Health COVID-19 NeuroDatabank and NeuroBiobank: A National Resource for Learning, Discovery, and Progress

Troxel, Andrea B; Frontera, Jennifer A; Mendoza-Puccini, Carolina
Patients suffering from COVID-19 experience a wide range of symptoms and sequelae, including increasingly recognized neurological problems. A concerted effort is necessary to identify and characterize these issues, whether newly appearing as a result of COVID-19 disease or exacerbations of underlying conditions. A national resource to collect information and/or biospecimens regarding neurological complications of COVID-19 offers an opportunity for broad representation, harmonization, and rapid learning, all while ensuring robust protection of confidential information through the use of global unique identifiers to protect patient privacy.
PMCID:7843568
PMID: 33519693
ISSN: 1664-2295
CID: 4799602